3/15/2012

Okairos initiated a midstage trial of a gene-based preventive vaccine against hepatitis C using NIH funding. While most vaccines prompt an antibody response, Okairos' vaccine is designed to stimulate T cells, which help the body combat disease.

Full Story:
Bloomberg

Related Summaries